1. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study. Issue 6 (8th October 2018) Authors: Mahlangu, Johnny; Oldenburg, Johannes; Callaghan, Michael U.; Shima, Midori; Santagostino, Elena; Moore, Maggie; Recht, Michael; Garcia, Claudia; Yang, Renchi; Lehle, Michaela; Macharia, Harrison; Asikanius, Elina; Levy, Gallia G.; Kruse‐Jarres, Rebecca Journal: Haemophilia Issue: Volume 24:Issue 6(2018) Page Start: 921 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS). Issue 3 (24th April 2019) Authors: Mahlangu, Johnny; Oldenburg, Johannes; Callaghan, Michael U.; Shima, Midori; Mancuso, Maria Elisa; Trask, Peter; Recht, Michael; Garcia, Claudia; Yang, Renchi; Lehle, Michaela; Macharia, Harrison; Asikanius, Elina; Levy, Gallia G.; Kruse‐Jarres, Rebecca; von Mackensen, Sylvia Journal: Haemophilia Issue: Volume 25:Issue 3(2019) Page Start: 382 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. (January 2023) Authors: Swain, Sandra M.; Tan, Antoinette R.; Gianni, Luca; Kuemmel, Sherko; Dang, Chau T.; Schneeweiss, Andreas; O'Shaughnessy, Joyce; Liu, Haiying; Aguila, Christian; Heeson, Sarah; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora; Loibl, Sibylle Journal: European journal of cancer Issue: Volume 178(2023) Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. Issue 5 (10th February 2022) Authors: Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Hervé; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiy... Journal: Journal of clinical oncology Issue: Volume 40:Issue 5(2022) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗